Donald J. Hayden, Jr. Sells 15,000 Shares of Insmed, Inc. (INSM) Stock

Insmed, Inc. (NASDAQ:INSM) Director Donald J. Hayden, Jr. sold 15,000 shares of the stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $32.50, for a total transaction of $487,500.00. Following the completion of the sale, the director now directly owns 71,131 shares of the company’s stock, valued at approximately $2,311,757.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Insmed, Inc. (NASDAQ INSM) opened at $30.33 on Friday. Insmed, Inc. has a 1 year low of $11.49 and a 1 year high of $32.94. The company has a current ratio of 15.21, a quick ratio of 15.21 and a debt-to-equity ratio of 0.13.

ILLEGAL ACTIVITY WARNING: “Donald J. Hayden, Jr. Sells 15,000 Shares of Insmed, Inc. (INSM) Stock” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://sportsperspectives.com/2017/11/18/donald-j-hayden-jr-sells-15000-shares-of-insmed-inc-insm-stock.html.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company lifted its stake in Insmed by 0.4% during the second quarter. The Manufacturers Life Insurance Company now owns 49,163 shares of the biopharmaceutical company’s stock worth $844,000 after purchasing an additional 197 shares during the last quarter. Legal & General Group Plc lifted its stake in Insmed by 2.0% during the second quarter. Legal & General Group Plc now owns 20,173 shares of the biopharmaceutical company’s stock worth $347,000 after purchasing an additional 390 shares during the last quarter. Parametric Portfolio Associates LLC lifted its stake in Insmed by 11.2% during the second quarter. Parametric Portfolio Associates LLC now owns 16,035 shares of the biopharmaceutical company’s stock worth $275,000 after purchasing an additional 1,618 shares during the last quarter. TIAA CREF Investment Management LLC lifted its stake in Insmed by 0.9% during the second quarter. TIAA CREF Investment Management LLC now owns 213,525 shares of the biopharmaceutical company’s stock worth $3,664,000 after purchasing an additional 1,857 shares during the last quarter. Finally, Voya Investment Management LLC lifted its stake in Insmed by 9.3% during the second quarter. Voya Investment Management LLC now owns 27,960 shares of the biopharmaceutical company’s stock worth $480,000 after purchasing an additional 2,389 shares during the last quarter. Hedge funds and other institutional investors own 74.26% of the company’s stock.

Several analysts have issued reports on INSM shares. Stifel Nicolaus reaffirmed a “buy” rating and issued a $43.00 price objective (up previously from $27.00) on shares of Insmed in a research report on Wednesday, September 6th. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Insmed in a research report on Monday, November 6th. Zacks Investment Research downgraded shares of Insmed from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Cowen and Company reaffirmed an “outperform” rating and issued a $54.00 price objective on shares of Insmed in a research report on Wednesday, September 6th. Finally, BidaskClub downgraded shares of Insmed from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $34.50.

About Insmed

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Receive News & Ratings for Insmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply